Johnson & Johnson (JNJ) shares rose 0.4% in early trading Friday after the company received U.S. Food and Drug Administration (FDA) approval for its RYBREVANT FASPRO (amivantamab combined with hyaluronidase) to be used alongside lazertinib as a first-line treatment for EGFR-mutated non-small cell lung cancer. The therapy enables subcutaneous administration in just five minutes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments